Special protocol assessment final guidance
Executive Summary
FDA's 1special protocol assessment guidance, issued May 17, makes "minor changes" to the draft "to make the document more clear." The draft guidance was released in February 2000 (2"The Pink Sheet" Feb. 14, 2000, p. 18). The House Commerce/Oversight Subcommittee is examining special protocol assessments in connection with its investigation into ImClone's BLA for Erbitux (3"The Pink Sheet" March 25, p. 20)...
You may also be interested in...
FDA Refuse-To-File Policy Records Requested Under House ImClone Probe
The House Commerce/Oversight Subcommittee is asking FDA to provide records relating to its policy on refuse-to-file letters, as part of its broadening investigation into ImClone
NonStandard Stability Protocols May Receive FDA Special Assessment Review
General sponsor inquiries regarding the adequacy of a protocol should not be addressed under FDA's special protocol assessment provisions, the agency said in a Feb. 8 draft guidance on special protocol assessment.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”